Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 4, 2007, Pages 441-445

  Pavlakis, Kitty ^a,e   Kountourakis, Panteleimon ^a,b   Stathopoulos, Efstathios ^c   Psyrri, Amanda ^a,b   Rontogianni, Dimitra ^d   Kafousi, Maria ^c   Derivianaki, Maria ^c   Xiros, Nikolaos ^a   Pectasides, Dimitrios ^a   Economopoulos, Theofanis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b YALE CANCER CENTER   (United States)

^c UNIVERSITY OF CRETE   (Greece)

^d EVANGELISMOS HOSPITAL   (Greece)

^e NONE   (Greece)

Author keywords

Colorectal cancer; Fluorescence in situ hybridization; Gene amplification; Her 2

Indexed keywords

CYTOPLASM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MEMBRANE PROTEIN; PARAFFIN;

ADENOCARCINOMA; ARTICLE; CANCER GRADING; CANCER STAGING; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; CROSS REACTION; CYTOPLASM; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPPA STATISTICS; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 37349013238     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213156.94804.b5     Document Type: Article

References (28)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe. Ann Oncol. 2005;16:481-488.
2. Midgley RS, Kerr DJ. Colorectal cancer. Lancet. 1999;353:391-399.
3. Midgley RS, Kerr DJ. Adjuvant treatment of colorectal cancer. Cancer Treat Rev. 1997;23:135-152.
4. Salomon D, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
5. Olayioye M, Neve R, Lane H, et al. The ERBB signaling network: receptor heterodimerization in development and cancer. Embo J. 2000;19:3159-3167.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med. 2001;344:783-792.
7. Menard S, Casalini M, Campiglio M, et al. HER2 over-expression in various tumour types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol. 2001;12(suppl 1):S15-S19.
8. Kay EW, Walsh BCJ, Cassidy M, et al. C-erbB2 immunostaining: problems with interpretation. J Clin Pathol. 1994;47:816-822.
9. Corbett IP, Henry JA, Angus B, et al. NCL-B11, a new monoclonal antibody recognising the internal domain of the C-ERBB2 oncogene protein effective for use on formalin-fixed paraffin embedded tissue. J Pathol. 1990;161:15-25.
10. Kapitanovic S, Radosevic S, Kapitanovic M, et al. The expression of p185 HER-2/neu correlates with the stage of disease and survival in colorectal cancer. Gatroenterology. 1997;112:1103-1113.
11. Jacombs TW, Gowm AM, Yaziji H, et al. Specificity of Hercep test in determing HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1983-1987.
12. Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol. 2005;36:250-261.
13. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science. 1987;35:77-82.
14. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 over-expressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
15. Van der Burg MEL, Henzen-Logmans SC, Foekens JA, et al. The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand assays, in primary epithelian ovarian cancer: a pilot study. Eur J Cancer. 1993;29A:1951-1957.
16. Lee JC, Wang S-T, Chow N-H, et al. Investigation of the prognostic value of co-expressed ErBb family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer. 2002;38:1065-1071.
17. Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of Her-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol. 2004;7:895-904.
18. Nathanson DR, Culliford IV AT, Jinru SHIA, et al. Her-2/neu expression and gene amplification in colon cancer. Int J Cancer. 2003;05:796-802.
19. Osako T, Miyahara M, Uchino S, et al. Immunohistochemical study of C-ERBB2 protein in colorectal cancer and the correlation with patient survival. Oncology. 1998;5:548-555.
20. Chamberlain NL, Ward RL, Hawkins NJ. Clinicopathological significance of CERB-B2 expression in colorectal carcinoma. Oncol Rep. 1999;6:527-531.
21. Essapen S, Thomas H, Green M, et al. The expression and prognostic significance of Her-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol. 2004;4:241-248.
22. De Potter CR, Quatacuer J, Maertens G, et al. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer. 1989;44:869-974.
23. Half E, Broaddus R, Danenberg KD, et al. Her-2 receptor expression, localization and activation in colorectal cancer cell lines and human tumours. Int J Cancer. 2004;08:540-548.
24. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR,ERBB2, ERBB3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000;1:105-115.
25. Slikowski MX, Du Bois NR. Her-2/neu overexpression in colonic malignancies. Gastroenterology. 2002;22:248-249.
26. Kraus MH, Popescu NC, Amsbaugh SC, et al. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987;6:605-610.
27. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;7:S3-S8.
28. Coombs LM, Oliver S, Sweeney E, et al. Immunocytochemical localization of c-erbB2 protein in transitional cell carcinoma of the urinary bladder. J Pathol. 1993;69:35-42.